PATENT CLAIM ANALYSIS

Application Number: 16028228
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-12
Patent Classification: ["514", "252120"]

Abstract:
The present invention provides a composition and method for treating acute on chronical liver failure or a related disease. The method comprises administering to a subject a composition comprising trimetazidine hydrochloride (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) (Trimetazidine or TMZ) or a pharmaceutically acceptable salt thereof according to a dosage regimen.

Claim (Index 16):
The method according to  claim 1 , wherein the related disorder is selected from the group consisting of viral hepatitis, non-specific virus hepatitis, drug or medication induced liver injury or damage, toxin induced hepatitis such as herbs or mushroom induced hepatitis or hepatopathy, alcoholic hepatitis, autoimmune hepatitis, alcoholic fatty liver disease, or non alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH), metabolic or genetically related liver diseases (Hemochromatosis, Wilson's diseases), ischemic liver injury (shock live), sepsis (bacteria or other microorganism infection) induced liver failure, and congestive hepatopathy (heart failure induced liver failure).

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.32558
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14891746', '15092533', '11602571', '14326075', '12713497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7434013833559091
- 35 USC 102 Novelty (BERT): 0.491592283571389
- Combined Prediction Score: 0.7182204733774571
- Mean Citation Score: 190.156372
- Max Citation Score: 196.69803
- Similarity Product: 132.8828565258032

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test